<HashMap><database>MassIVE</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://massive-ftp.ucsd.edu/v10/MSV000098630/</Other></files><type>primary</type></body><statusCode>OK</statusCode><statusCodeValue>200</statusCodeValue></file_versions><scores/><additional><omics_type>Proteomics</omics_type><submitter>Kevin D Houston</submitter><instrument_platform>Orbitrap Eclipse</instrument_platform><species>Homo Sapiens (ncbitaxon:9606)</species><full_dataset_link>https://massive.ucsd.edu/ProteoSAFe/dataset.jsp?task=d75d887c0bc2421d95e23ec4416dc4bb</full_dataset_link><submitter_email>khouston@nmsu.edu</submitter_email><submitter_affiliation>New Mexico State University</submitter_affiliation><sample_protocol></sample_protocol><repository>MassIVE</repository><file_size>115</file_size><ptm_modification>UNIMOD:21 - "Phosphorylation."</ptm_modification><data_protocol></data_protocol><pubmed_abstract>While the contribution of the IGF-signaling axis in breast cancer is well-documented, the role of IGFBP-6 in breast carcinogenesis has not been extensively studied. In general, insulin-like growth factor binding protein-6 (IGFBP-6) sequesters insulin-like growth factor 2 (IGF-2) to attenuate activation of its cognate receptor IGF-1R. To reveal previously unknown mechanisms of breast cancer modulation by IGFBP-6 in breast cancer, proteomic analysis was performed in T47D cells after IGFBP-6 knockdown. Comparing protein expression and phosphosites after knockdown by unique siRNA sequences with a negative control and subsequent pathway analysis, a decrease in IGFBP-6 expression resulted in activation of interferon signaling pathways and a decrease in pathways involved in the G2/M cell cycle transition. A subset of the proteins identified in each cell regulatory pathway was validated by immunoblotting for specific proteins after IGFBP-6 knockdown. Cell cycle analysis showed that IGFBP-6 knockdown in Hormone Receptor Positive T47D breast cancer cells resulted in an increased number of cells in the G1 phase and a decrease in cells in G2, indicating a role for IGFBP-6 in cell cycle regulation. Knockdown of IGFBP-6 in a triple-negative breast cancer cell line, MDA-MB-231, also resulted in a decrease in Cyclin B1 accumulation, demonstrating that our observations are not cell line specific. Taken together, our results demonstrate that IGFBP-6 regulates cell cycle progression in breast cancer cells and interferon signaling in hormone-positive cells.</pubmed_abstract><pubmed_title>IGFBP-6 regulates breast cancer cell cycle progression by promoting exit out of G1.</pubmed_title><pubmed_authors>Lariz Francisco J FJ, Hernandez Shayla S, Bautista-Tovar Diana C DC, Houston Kevin D KD</pubmed_authors></additional><is_claimable>false</is_claimable><name>IGFBP-6 is a Regulator of Cell Cycle Progression by Promoting Exit Out of G1</name><description>These data are for phosphoproteomic analysis of T47D Breast Cancer Cells treated with siRNA targeting IGFBP-6. </description><dates><publication>Thu Jul 24 03:58:00 BST 2025</publication></dates><accession>MSV000098630</accession><cross_references><pubmed>41419198</pubmed></cross_references></HashMap>